Trending...
- Nayarit Strengthens Its Position as a Global Surf Destination; Sayulita to Become Mexico's First Official Surf City
- HomeCentris Healthcare Signs Definitive Agreement to Acquire S&K Holdings, Expanding Mid Atlantic Platform
- Sylvester Anthony III Introduces His Artist Journey with Debut Single "Cherish"
New preclinical research reports that HuMOLYTE®, a magnesium-containing medical food with 2′-fucosyllactose, reduced chemotherapy-induced gastrointestinal and oral mucosal injury in Wistar rats
SACRAMENTO, Calif. - illiNews -- IGH Naturals announced that a peer-reviewed original research study evaluating HuMOLYTE® has been accepted and published in Frontiers in Nutrition. The study, titled "Supplementation with 2′-fucosyllactose, a prebiotic human milk oligosaccharide (HMO), in a magnesium-containing medical food reduces chemotherapy-induced mucositis in Wistar rats," reports preclinical findings on HuMOLYTE®, a medical food formulated with 2′-fucosyllactose, magnesium, sodium, and potassium.
Chemotherapy-induced mucositis is a common and difficult side effect of cancer treatment that can affect the mouth and gastrointestinal tract. It may contribute to painful oral symptoms, diarrhea, dehydration, electrolyte loss, poor nutrition, and interruptions in treatment. For patients and caregivers, these complications can add physical and emotional strain during an already challenging time.
More on illi News
The newly published study evaluated HuMOLYTE® in Wistar rats exposed to commonly used chemotherapy agents, including doxorubicin, irinotecan, 5-fluorouracil, and cisplatin. According to the publication, HuMOLYTE® supplementation was associated with reduced severity of chemotherapy-induced diarrhea, less chemotherapy-associated weight loss, and preservation of gastrointestinal mucosal structure, including goblet cells.
The study also reported reduced inflammation in ileal, colonic, and oral mucosal tissue among animals supplemented with HuMOLYTE®. In laboratory cell studies, HuMOLYTE® improved goblet cell survival, supported mucin secretion, and helped maintain epithelial barrier function.
"This publication marks an important milestone for IGH Naturals and HuMOLYTE®," said Dr. Sourabh Kharait, corresponding author of the study. "While these findings are preclinical and require confirmation in human clinical trials, they provide a strong scientific foundation for further investigation of HuMOLYTE® as a supportive nutrition strategy for chemotherapy-related mucositis."
More on illi News
The authors noted that chemotherapy-induced mucositis remains an area of high unmet need, with few consistently effective preventive therapies available. The study concluded that an oral rehydration mix containing 2′-fucosyllactose HMO and electrolytes may have potential as a food-grade approach to supporting oral hydration and electrolyte repletion during chemotherapy.
IGH Naturals emphasizes that the findings are based on animal and in vitro studies. HuMOLYTE® is not intended to diagnose, treat, cure, or prevent disease. Patients should speak with their oncology care team before adding any medical food or nutrition product during cancer treatment.
IGH Naturals is a nutrition-focused company developing science-backed medical foods and supportive nutrition products for people facing complex health challenges. HuMOLYTE® is the company's medical food formulated to support hydration and electrolyte repletion with 2′-fucosyllactose, magnesium, sodium, and potassium.
Chemotherapy-induced mucositis is a common and difficult side effect of cancer treatment that can affect the mouth and gastrointestinal tract. It may contribute to painful oral symptoms, diarrhea, dehydration, electrolyte loss, poor nutrition, and interruptions in treatment. For patients and caregivers, these complications can add physical and emotional strain during an already challenging time.
More on illi News
- Data Tiles Introduces the Decision-Driven Enterprise to North America
- Disruptor Creations Pioneers New MicroAdventure Series with TravelSpike
- Chicago Show of Buffalo Grove, IL, Acquired by an Individual Entrepreneur of Grand Rapids, MI
- eCopier Solutions Surpasses 3,000 Five-Star Google Reviews and Maintains Perfect Five-Star Rating
- Creative Investment Research Welcomes Supreme Court Decision Protecting Federal Reserve Independence While Calling for Continued Accountability
The newly published study evaluated HuMOLYTE® in Wistar rats exposed to commonly used chemotherapy agents, including doxorubicin, irinotecan, 5-fluorouracil, and cisplatin. According to the publication, HuMOLYTE® supplementation was associated with reduced severity of chemotherapy-induced diarrhea, less chemotherapy-associated weight loss, and preservation of gastrointestinal mucosal structure, including goblet cells.
The study also reported reduced inflammation in ileal, colonic, and oral mucosal tissue among animals supplemented with HuMOLYTE®. In laboratory cell studies, HuMOLYTE® improved goblet cell survival, supported mucin secretion, and helped maintain epithelial barrier function.
"This publication marks an important milestone for IGH Naturals and HuMOLYTE®," said Dr. Sourabh Kharait, corresponding author of the study. "While these findings are preclinical and require confirmation in human clinical trials, they provide a strong scientific foundation for further investigation of HuMOLYTE® as a supportive nutrition strategy for chemotherapy-related mucositis."
More on illi News
- DemandView Launches EngageSMS — B2B' Demand Gens First Text Message Lead Nurture Engine
- Chicago: Mayor Brandon Johnson, Department of Housing Introduce The Protecting Renters Ordinance
- Mayor Brandon Johnson, Department of Family and Support Services, and Chicago Early Learning to Host Second "Chicago's Largest Playdate" Celebrating America 250 at Humboldt Park
- Pocket Wipe Introduces a Smarter Approach to Everyday Personal Hygiene
- Ascent Solar Technologies (N A S D A Q: ASTI): Positioned at the Intersection of the New Space Economy, Defense Innovation and Next-Generation Energy
The authors noted that chemotherapy-induced mucositis remains an area of high unmet need, with few consistently effective preventive therapies available. The study concluded that an oral rehydration mix containing 2′-fucosyllactose HMO and electrolytes may have potential as a food-grade approach to supporting oral hydration and electrolyte repletion during chemotherapy.
IGH Naturals emphasizes that the findings are based on animal and in vitro studies. HuMOLYTE® is not intended to diagnose, treat, cure, or prevent disease. Patients should speak with their oncology care team before adding any medical food or nutrition product during cancer treatment.
IGH Naturals is a nutrition-focused company developing science-backed medical foods and supportive nutrition products for people facing complex health challenges. HuMOLYTE® is the company's medical food formulated to support hydration and electrolyte repletion with 2′-fucosyllactose, magnesium, sodium, and potassium.
Source: IGH Naturals
Filed Under: Health
0 Comments
Latest on illi News
- Sylvester Anthony III Introduces His Artist Journey with Debut Single "Cherish"
- BCD Meetings & Events Client Survey Finds Cost Pressures and ROI Driving Priorities in 2026
- Boston Industrial Solutions Introduces High-Performance Primer for Bonding Liquid Silicone to Epoxy
- Healthcare Leaders Publish New Integrated Behavioral Healthcare Guide, Led by Doctors of Behavioral Health
- Verbica Challenges Panetta to a Televised Debate on the Issues
- Chicago: Mayor Brandon Johnson Signs Executive Order Establishing Office of Gun Violence Reduction
- Salt Lake City Families Turn to Private Autopsy Services for Faster Answers After Unexpected Loss
- Naperville: Structure Fire in the 1000 Block of Devonshire Court
- K2 Integrity's U.S. and EMEA Teams Again Recognized in Chambers and Partners 2026 Guides
- Connecta Satellite Solutions Ready to Support Emergency Communications Following the Venezuela Earthquake
- Rare 1933 Harold Weston painting will be auctioned to benefit the Keene Valley Library
- $20 Million Revenue Target, Accelerating Growth, 7% Of Outstanding Shares Retired, Clear Path Toward Profitability: VSee Health, Inc N A S D A Q: VSEE
- HomeCentris Home Health Achieves 5-Star CMS Rating
- Top 10 AI Robots: AI Trading Yields 356% Annualized Return for Retail Traders (SATS)
- Adsoptia Launches AI-Powered Optimization Platform for a New Era of Autonomous Marketing Decisions
- Heritage at Manalapan Announces New Incentive: Included Finished Basement on Select Homesites
- Leicester UK Manufacturer Tabletop Tyrant Secures Flawless 100% Customer Satisfaction Rating Across 5,800+ Orders
- Quality Inn O'Fallon to Host Ribbon Cutting Celebrating a New Chapter and Launch of Business
- Chicago: Mayor Brandon Johnson Celebrates National Immigrant Heritage Month, Awarding of 4-Star Certified Welcoming Designation
- Naperville Police Begin Fourth of July Crackdown on Impaired Drivers and Seat Belt Law Violators
